Variability in total serum IgE over 1 year in severe asthmatics.

Background: Immunoglobulin E (IgE) is the treatment target of omalizumab, a monoclonal antibody indicated in the treatment of severe allergic asthma. Long-term variability of serum total IgE (sIgE) in asthmatics remains poorly documented.

Methods: In this prospective study, sIgE levels were measured over 1 year at 7 time points in 41 severe asthmatics treated with high-dose of inhaled corticosteroids and long-acting β agonists.